Efficacy of Xuebijing Injection for Sepsis (EXIT-SEP): protocol for a randomised controlled trial

Songqiao Liu, Chen Yao, Junhua Zhang, Yi Yang, Haibo Qiu, EXIT-SEP Investigators, Songqiao Liu, Chen Yao, Junhua Zhang, Yi Yang, Haibo Qiu, EXIT-SEP Investigators

Abstract

Introduction: Sepsis is a major challenge with high incidence and is associated with high mortality worldwide. Current management of sepsis remains mainly supportive except for treatment with antibiotics. Both basic research and clinical investigation have shown that the Chinese herbal-derived therapeutic Xuebijing (XBJ) injection is beneficial for patients with sepsis. However, the quality of evidence supporting the therapeutic use of XBJ in sepsis is limited. The aim of this trial is to evaluate the Efficacy of Xuebijing Injection for Sepsis, compared with a placebo, on the outcome of patients with sepsis in the intensive care unit (ICU).

Methods and analysis: In this multicentre, blinded randomised controlled trial, we are recruiting a total of 1800 subjects who met Sepsis 3.0 criteria. Subjects will be randomised (1:1) to receive XBJ, every 12 hours for 5 days or a matching placebo and usual care. The primary outcome is 28 days all-cause mortality. Secondary outcomes will be the improvement of Sequential Organ Failure Assessment scores, the improvement of the Acute Physiology and Chronic Health Evaluation II score, duration of mechanical ventilation, mortality in ICU and duration of stay in the ICU. Investigators, participants and statisticians will be blinded to the allocated treatment.

Ethics and dissemination: This trial has been approved by all ethics committees of the centres that will participate in this trial. The findings of the study will be disseminated in peer-reviewed journals and present at conferences. Once this study is complete, the results of this trial may help provide evidence-based recommendations for complementary therapeutic options for patients with sepsis.

Trial registration number: NCT03238742 and ChiCTR-IPR-17012713.

Keywords: Xuebijing injection; protocol; randomised controlled trial; sepsis.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
The flow chart of the Efficacy of Xuebijing Injection for Sepsis (EXIT-SEP) study. XBJ, Xuebijing.

References

    1. Rhodes A, Evans LE, Alhazzani W, et al. . Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017;45:486–552. 10.1097/CCM.0000000000002255
    1. Singer M, Deutschman CS, Seymour CW, et al. . The third International consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–10. 10.1001/jama.2016.0287
    1. Fleischmann C, Scherag A, Adhikari NKJ, et al. . Assessment of global incidence and mortality of Hospital-treated sepsis. current estimates and limitations. Am J Respir Crit Care Med 2016;193:259–72. 10.1164/rccm.201504-0781OC
    1. Delano MJ, Ward PA. Sepsis-Induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest 2016;126:23–31. 10.1172/JCI82224
    1. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ 2016;353:i1585 10.1136/bmj.i1585
    1. Paul M, Shani V, Muchtar E, et al. . Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54:4851–63. 10.1128/AAC.00627-10
    1. Annane D. Adjunct therapy for sepsis: how early? Curr Infect Dis Rep 2010;12:361–7. 10.1007/s11908-010-0123-2
    1. Zhang N, Cheng C, Olaleye OE, et al. . Pharmacokinetics-Based identification of potential therapeutic phthalides from XueBiJing, a Chinese herbal injection used in sepsis management. Drug Metab Dispos 2018;46:823–34. 10.1124/dmd.117.079673
    1. Chen S, Dai G, Hu J, et al. . Discovery of Xuebijing injection exhibiting protective efficacy on sepsis by inhibiting the expression of HMGB1 in septic rat model designed by cecal ligation and puncture. Am J Ther 2016;23:e1819–25. 10.1097/MJT.0000000000000296
    1. Jiang M, Zhou M, Han Y, et al. . Identification of NF-κB inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q/TOF. J Ethnopharmacol 2013;147:426–33. 10.1016/j.jep.2013.03.032
    1. He X-D, Wang Y, Wu Q, et al. . Xuebijing protects rats from sepsis challenged with Acinetobacter baumannii by promoting annexin A1 expression and inhibiting proinflammatory cytokines secretion. Evid Based Complement Alternat Med 2013;2013:804940 10.1155/2013/804940
    1. Wang Q, Wu X, Tong X, et al. . Xuebijing ameliorates sepsis-induced lung injury by downregulating HMGB1 and RAGE expressions in mice. Evid Based Complement Alternat Med 2015;2015:860259:1–9. 10.1155/2015/860259
    1. Li C, Wang P, Zhang L, et al. . Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a meta-analysis of randomized controlled trials. J Ethnopharmacol 2018;224:512–21. 10.1016/j.jep.2018.05.043
    1. Shi H, Hong Y, Qian J, et al. . Xuebijing in the treatment of patients with sepsis. Am J Emerg Med 2017;35:285–91. 10.1016/j.ajem.2016.11.007
    1. Yin Q, Li C. Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation. Evid Based Complement Alternat Med 2014;2014:1–6. 10.1155/2014/949254
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. . Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586 10.1136/bmj.e7586
    1. LIU S-qiao, ZHENG R-qiang, LI M-qin, et al. . [Effect of Xuebijing injection treatment on acute respiratory distress syndrome: a multicenter prospective randomized control clinical trial]. Zhonghua Yi Xue Za Zhi 2012;92:1017–22.
    1. Jiang W, Yu X, Sun T, et al. . Adjunctive Ulinastatin in sepsis treatment in China (adjust study): study protocol for a randomized controlled trial. Trials 2018;19:133 10.1186/s13063-018-2513-y
    1. Zhang S-wen, Sun C-dong, Wen Y, et al. . [Effect of treatment with Xuebijing injection on serum inflammatory mediators and Th1/2 of spleen in rats with sepsis]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2006;18:673–6.
    1. Raith EP, Udy AA, Bailey M, et al. . Australian, New Zealand intensive care Society centre for O, resource E: prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA 2017;317:290–300.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe